Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-08-2017 | Retinal Disorders

Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy

Authors: Tsutomu Sakai, Noriko Kato, Masaomi Kubota, Hiroshi Tsuneoka

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2017

Abstract

Purpose

To evaluate the outcome of triple therapy of photodynamic therapy combined with injections of intravitreal aflibercept (IVA) and subtenon triamcinolone acetonide for polypoidal choroidal vasculopathy (PCV) resistant to IVA.

Methods

A retrospective chart review at a single institution was conducted to identify patients with PCV resistant to treatment with IVA who were switched to treatment with triple therapy. In total, 13 eyes from 13 patients were included in the study. Demographic data, visual acuities, central retinal thickness (CRT) and height of pigment epithelial detachment (PED) on optical coherence tomography (OCT), complications, and number of injections were reviewed.

Results

The patients had a mean age of 68 years (range 53–83). The number of prior injections with IVA ranged from 5 to 10. At 12 months follow-up after triple therapy, there was a significant improvement in visual acuity (P = 0.0039), a significant decrease in CRT (P = 0.003), and a significant reduction of the height of PED (P = 0.015). Only one patient had retinal pigment epithelium tear.

Conclusions

Triple therapy improved visual and anatomical outcomes in patients with PCV with recurrent or resistant retinal fluid and PED after multiple injections with IVA.

Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8CrossRefPubMed

Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110CrossRefPubMed

Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA (1997) The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 115:478–485CrossRefPubMed

Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA (2004) Polypoidal choroidal vasculopathy. Surv Ophthalmol 49:25–37CrossRefPubMed

Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M (2004) Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 88:809–815CrossRefPubMedPubMedCentral

Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462CrossRefPubMed

Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, Nishio K, Taki K, Niwa T, Hamajima N, Terasaki H (2007) Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 114:1722–1727CrossRefPubMed

Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T (2002) Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol 86:321–327CrossRefPubMedPubMedCentral

Stewart MW (2012) Aflibercept (VEGF trap-eye): the newest anti-VEGF drug. Br J Ophthalmol 96:1157–1158CrossRefPubMedPubMedCentral

10.

Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, Ueda-Arakawa N, Miyake M, Akagi-Kurashige Y, Hata M, Yoshikawa M, Kuroda Y, Takahashi A, Yoshimura N (2015) One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol 159:853–860CrossRefPubMed

11.

Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T (2015) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866–1872CrossRefPubMed

12.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123:617–624CrossRefPubMed

13.

Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92:661–666CrossRefPubMed

14.

Sato T, Kishi S, Matsumoto H, Mukai R (2010) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 149:947–954CrossRefPubMed

15.

Lee YA, Yang CH, Yang CM, Ho TC, Huang JS, Chen MS (2012) Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up. Am J Ophthalmol 154:872–880CrossRefPubMed

16.

Sakai T, Ohkuma Y, Kohno H, Hayashi T, Watanabe A, Tsuneoka H (2014) Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy. Br J Ophthalmol 98:1642–1648CrossRefPubMed

17.

Fauser S, Schwabecker V, Muether PS (2014) Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 158:532–536CrossRefPubMed

18.

Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M (2015) Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci 56:6501–6505CrossRefPubMed

19.

Fauser S, Muether PS (2016) Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol 100:1494–1498CrossRefPubMed

20.

Lai TY, Lam CP, Luk FO, Chan RP, Chan WM, Liu DT, Lam DS (2010) Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 26:91–95CrossRefPubMed

21.

Yoshizawa C, Saito W, Hirose S, Kitamei H, Noda K, Ishida S (2013) Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Jpn J Ophthalmol 57:68–73CrossRefPubMed

22.

Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M (2016) One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefe Arch Clin Exp Ophthalmol. doi:10.1007/s00417-016-3500-1

23.

Takayama K, Kaneko H, Kataoka K, Ueno S, Chang-Hua P, Ito Y, Terasaki H (2016) Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy. Graefe Arch Clin Exp Ophthalmol. doi:10.1007/s00417-016-3468

24.

Kang HM, Koh HJ (2013) Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 156:652–660CrossRefPubMed

25.

Chang YS, Kim JH, Kim KM, Kim JW, Lee TG, Kim CG, Cho SW (2016) Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 32:219–224CrossRefPubMed

26.

Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R, Fujisan Study Group (2015) Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy. Retina 35:1569–1576CrossRefPubMed

27.

Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73CrossRefPubMed

28.

Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6 month results. Br J Ophthalmol 94:297–301CrossRefPubMed

29.

Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ (2011) One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 31:846–856CrossRefPubMed

30.

Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Nishida K (2012) Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol 96:394–399CrossRefPubMed

Title: Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy
Authors: Tsutomu Sakai
Noriko Kato
Masaomi Kubota
Hiroshi Tsuneoka
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3700-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2017

Blood vessel segmentation in color fundus images based on regional and Hessian features

Ciliary body thickness changes after preoperative anti-inflammatory treatment in rhegmatogenous retinal detachment complicated by choroidal detachment

Blockade of MMP-2 and MMP-9 inhibits corneal lymphangiogenesis

Study of conjunctival flora in anophthalmic patients: influence on the comfort of the socket

Challenges with cataract surgery in pars planitis patients

A novel MERTK mutation causing retinitis pigmentosa